The immunogenicity of experimental tumors is strongly biased by the expression of dominant viral cytotoxic T-lymphocyte epitopes

Cancer Research

Volumn 57, Issue 13, 1997, Pages 2564-2568

  Iezzi, Giandomenica ^a   Rivolta, Loredana ^a   Ronchetti, Anna ^a   Martin Fontecha, Alfonso ^a   Rosato, Antonio ^b   Protti, Maria Pia ^c   Sabbadini, Maria Grazia ^a   Bellone, Matteo ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; T LYMPHOCYTE ANTIGEN; T LYMPHOCYTE RECEPTOR; VIRUS ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CROSS REACTION; CYTOTOXIC T LYMPHOCYTE; FRIEND LEUKEMIA VIRUS; IMMUNOGENICITY; MOLONEY LEUKEMIA ONCOVIRUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAUSCHER LEUKEMIA VIRUS; THYMOMA; TUMOR REJECTION; VIRUS CARCINOGENESIS;

ANIMALS; ANTIGENS, VIRAL; CYTOTOXICITY TESTS, IMMUNOLOGIC; FEMALE; FRIEND MURINE LEUKEMIA VIRUS; IMMUNODOMINANT EPITOPES; IMMUNOHISTOCHEMISTRY; LEUKEMIA VIRUS, MURINE; LEUKEMIA, EXPERIMENTAL; LYMPHOMA; MICE; MICE, INBRED C57BL; MOLONEY MURINE LEUKEMIA VIRUS; NEOPLASM TRANSPLANTATION; RAUSCHER VIRUS; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; THYMOMA; TUMOR CELLS, CULTURED; TUMOR VIRUS INFECTIONS; VACCINATION;

EID: 0030844464     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Zijlstra, M., and Melief, C. J. M. Virology, genetics and immunology of murine lymphomagenesis. Biochim. Biophys. Acta, 865: 197-231, 1986.
2. North, R. J. The murine antitumor immune response and therapeutic manipulation. Adv. Immunol., 35: 89-155, 1984.
3. Jaffe, E. M., and Pardoll, D. M. Murine tumor antigens: is it worth the search? Curr. Opin. Immunol., 8: 622-627, 1996.
4. Moyret, C. F., Bernard, D. J., Maruzis, J. C., Chollet, P., and Plagne, R. Detection of reverse transcriptase activity in human breast tumors. Anticancer Res., 8: 1279-1283, 1988.
5. Collavo, D., Colombatti, A., Biasi, G., Chieco-Bianchi, L., and Davies, A. J. S. Immune reactivity in the Moloney strain of murine sarcoma virus oncogenesis: requirement of thymus-derived lymphocytes for in vivo protection. J. Natl. Cancer Inst., 56: 603-608, 1976.
6. Old, J. P., and Stockert, E. Immunogenetics of cell surface antigens of mouse leukemia. Annu. Rev. Genet., 17: 127-160, 1977.
7. Glynn, J. P., McCoy, J. L., and Fefer, A. Cross-resistance to transplantation of syngeneic Friend. Moloney and Rauscher virus-induced tumors. Cancer Res., 28: 434-439, 1968.
8. Plata, F., and Lilly, F. Viral specificity of H-2 restricted T killer cells directed against syngeneic tumors induced by Gross, Friend or Rauscher leukemia virus. J. Exp. Med., 150: 1174-1186, 1979.
9. Old, L. J., Boyse, E. A., and Stockert, E. The G (Gross) leukemia antigen. Cancer Res., 25: 813-819, 1965.
10. Weiss, A., Brunner K. T., MacDonald, H. R., and Cerottini, J-C. Antigenic specificity of the cytolytic T lymphocyte response to murine sarcoma virus-induced tumors. III. Characterization of cytotoxic T lymphocyte clones specific for Moloney leukemia virus-associated cell surface antigens. J. Exp. Med., 752: 1210-1225, 1980.
11. gag as an antigen recognized by Moloney leukemia virus-specific cytolytic T cell clones that function in vivo. J. Exp. Med., 162: 128-144, 1985.
12. Ossendorp, F., Eggers, M., Neisig, A., Ruppert, T., Groettrup, M., Sijts A., Mengedé, E., Kloetzel, P-M., Neefjes, J., Koszinowski, U., and Melief, C. A single residue exchange within a viral CTL epitope alters proteasome-mediated degradation resulting in lack of antigen presentation. Immunity, 5: 115-124, 1996.
13. Rogers, M. J., Galetto, G., Hearing, V. J., Siwarski, D. F., and Law, L. W. Purification of a glycoprotein bearing a tumor transplantation antigen specific for Friend, Moloney, and Rauscher MuLV-induced tumors. J. Immunol., 132: 3211-3217, 1984.
14. Franksson, L., Petersson, M., Kiessling, R., and Karre, K. Immunization against tumor and minor histocompatibility antigens by eluted cellular peptides loaded on antigen processing defective cells. Eur. J. Immunol., 23: 2606-2613, 1993.
15. Iezzi, G., Protti, M. P., Rugarli, C., and Bellone, M. B7.1 expression on tumor cells circumvents the need of professional antigen presentation for in vitro propagation of cytotoxic T cell lines. Cancer Res., 56: 11-15, 1996.
16. Karre, K., Ljunggren, H-G, Piontek, G., and Kiessling, R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature (Lond.), 319: 675-678, 1986.
17. Chen, L., McGowan, P., Ashe, S., Johnston, J., Li, Y., Hellstrom, I., and Hellstrom, K. E. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J. Exp. Med., 179: 523-532, 1994.
18. Ljunggren, H-G., and Karre, K. Host resistance directed selectively against H-2 deficient lymphoma variants. J. Exp. Med., 162: 1745-1759, 1985.
19. Cavallo, F., Martin-Fontecha, A., Bellone, M., Heltai, S., Gatti, E., Tornaghi, P., Freschi, M., Forni, G., Dellabona, P., and Casorati, G. Co-expression of B7.1 and ICAM-1 on tumors is required for rejection and establishment of a memory response. Eur. J. Immunol., 25: 1154-1162, 1996.
20. Groer P. A. Studies in antibody response of mice to tumour inoculation. Br. J. Cancer, 4: 372-378, 1950.
21. Schrader, J. W., Cunningham, B. A., and Edelman, G. M. Functional interactions of viral and histocompatibility antigens at tumor cell surface. Proc. Natl. Acad. Sci. USA, 72: 5066-5070, 1975.
22. Chesebro, B., Wehrly, K., Cloyd, M., Britt, W., Portis, J., Collins, J., and Nishio, J. Characterization of mouse monoclonal antibodies specific for Friend murine leukemia virus-induced erythroleukemia cells: friend-specific and FMR-specific antigens. Virology, 112: 131-144, 1981.
23. Bellone, M., Iezzi, G., Manfredi, A. A., Protti, M. P., Dellabona, P., Casorati, G., and Rugarli, C. In vitro priming of cytotoxic T lymphocytes against poorly immunogenic epitopes by engineered antigen-presenting cells. Eur. J. Immunol., 24: 2691-2698, 1994.
24. Bellone, M., Ostlie, N., Lei, S., and Conti-Tronconi, B. M. Experimental myasthenia gravis in congenic mice: sequence mapping and H-2 restriction of T helper epitopes on the α subunits ot Torpedo californica and murine acetylcholine receptors. Eur. J. Immunol., 21: 2303-2310, 1991.
25. Bellone, M., Karachunski, P. I., Ostlie, N., Lei, S., and Conti-Tronconi, B. M. Preferential pairing of T and B cells for production of antibodies without covalent association of T and B epitopes. Eur. J. Immunol., 24: 799-804, 1994.
26. Johnston, J. V., Malacko, A. R., Mizuno, M. T., McGowan, M., Hellstrom, I., Hellstrom, K. E., Marquardt, H., and Chen, L. B7-CD28 costimulation unveils the hierarchy of tumor epitopes recognized by major histocompatibility complex class I-restricted CD8+ cytolytic T lymphocytes. J. Exp. Med., 183: 791-800, 1996.
27. Dudley, M. E., and Roopenian, D. C. Loss of a unique tumor antigen by cytotoxic T lymphocyte immunoselection from a 3-methylcholanthrene-induced mouse sarcoma reveals secondary unique and shared antigens. J. Exp. Med., 184: 441-447, 1996.
28. Holden, H. T., Haskin, J. S., Kirchner, H., and Herberman, R. B. Two functionally distinct anti-tumor effector cells isolated from primary murine sarcoma virus-induced tumors. J. Immunol., 117: 440-447, 1976.
29. Matzinger, P. Tolerance, danger and the extended family. Annu. Rev. Immunol., 12: 991-1045, 1994.